{"id":2390,"date":"2026-05-28T00:05:56","date_gmt":"2026-05-27T15:05:56","guid":{"rendered":"https:\/\/prismbiolab.com\/?p=2390"},"modified":"2026-05-28T00:06:46","modified_gmt":"2026-05-27T15:06:46","slug":"2390-2","status":"publish","type":"post","link":"https:\/\/prismbiolab.com\/ja\/2390-2\/","title":{"rendered":"Prostate Cancer and Radiopharmaceuticals of 177Lu, 225Ac and 213Bi"},"content":{"rendered":"
\n
\n\t

Prostate-specific membrane antigen (PSMA) is a promising target to achieve a selective delivery to prostate cancer.1)<\/sup> Even though its significance in cancer pharmacology is scarce, radiopharmaceuticals have been taken it as the target for the therapy and diagnostic purposes. PSMA targeting is the legendary story of radiopharmaceutical discovery and development and it is of high values to take a close look at for the better understanding of radiotherapy.<\/p>\n

In PSMA, glutamate carboxypeptidase II (GCPII), targeted radiotherapeutics development, three radionuclides, 177<\/sup>Lu, 225<\/sup>Ac and 213<\/sup>Bi, have been playing invaluable roles. 68<\/sup>Ga and 18<\/sup>F have also contributed for the diagnosis purpose in PET. We would like to focus here on the therapeutic side of PSMA-targeted radiotherapeutics.<\/p>\n

The concept of radiotherapy for prostate cancer is rather simple. A radiolabeled PSMA binder is supposed to be targeted to the tumor cells derived from PSMA-related prostate cancer. The decay of radionuclide emits a high energy particle (a or b-<\/sup>) or radiation (g) that inflict DNA strand and drive the tumor cells to death.<\/p>\n

177<\/sup>Lu, 225<\/sup>Ac and 213<\/sup>Bi have been used because of their reliable properties in terms of the y sequence and the resulting emission of locally targetable a and\/or b-<\/sup> particles.<\/p>\n

177<\/sup>Lu is a b-<\/sup> emitter and allows relatively local invasion. The energy of the b-<\/sup> particle depends on the decay pathway to177<\/sup>Hf and the distribution is analyzed to be 497 KeV (78.6 %), 384 keV (9.1 %) and 176 keV (12.2 %). The decays also involve low-energy g photons with energies of 113 keV (6.6 %) and 208 keV (11 %).2)<\/sup> 177<\/sup>Lu\u2019s decay emits low-penetrative particle with mean distance of 0.67mm.3)<\/sup> The cellular uptake of 177<\/sup>Lu-based radiopharmaceuticals allows cancer lesion-selective damages on the DNAs in the for single or double strand breaks. The half-life 6.6 days.4)<\/sup><\/p>\n

225<\/sup>Ac undergoes a decay to emit a particles with the energy of 5.8 to 8.4 MeV.5),6) <\/sup>The a ray of 225<\/sup>Ac travels within the distance of 0.085mm in tissues. It means 225<\/sup>Ac selectively shows strong invasive effects on the cells just around the nuclide considering the general radius of a cancel cell is 0.01mm or a bit more. 255<\/sup>Ac has a half-life of 9.9 days.<\/p>\n

213<\/sup>Bi is a mixed a and b-<\/sup> emitter with a half-life of only 45.6 minutes.7)<\/sup> In spite of the difficulty in the supply of the short-lived 213<\/sup>Bi, there is a report of clinical application to a patient of prostate cancer.8)<\/sup><\/p>\n

It is worth considering that 213<\/sup>Bi are present in the decay cascade of 225<\/sup>Ac. The sequence of decays from 225<\/sup>Ac to the stable nuclide, 205<\/sup>Tl, is below.<\/p>\n

225<\/sup>Ac-a-221<\/sup>Fr-a-217<\/sup>At-a-213<\/sup>Bi-b-<\/sup>-213<\/sup>Po-a- or -a-209<\/sup>Tl-b-<\/sup>-209<\/sup>Pb-b-<\/sup>-209<\/sup>Bi-a-205<\/sup>Tl<\/p>\n

The half-lives of the nuclides except for 209<\/sup>Bi (2x1019<\/sup> years) after the a decay of 225<\/sup>Ac are within hours to micro seconds, and hence 225<\/sup>Ac actually emits 4 a particles and 2 b-<\/sup> particles.<\/p>\n

177<\/sup>Lu has been the major nuclide in PSMA-targeted radiopharmaceutical therapies.9)<\/sup> However, application of 225<\/sup>Ac in the same scheme is an intense focus of area because of its ability to emit multiple a particles that allows more local irradiation and hence expected less adverse effects on non-cancer cells.10)<\/sup><\/p>\n

The approaches for radiopharmaceuticals developments are different from the other drug discovery and developments. There is orthogonality in target identification and approach for drug improvement, which we did not discuss here deeply. It is worth keep eyes on radiopharmaceuticals in cancer therapy to see the possibility of opening up their opportunity.<\/p>\n

    \n
  1. https:\/\/doi.org\/10.3390\/bioengineering11070714<\/a><\/li>\n
  2. https:\/\/doi.org\/10.1007%2Fs13139-014-0315-z<\/a><\/li>\n
  3. https:\/\/www.fda.gov\/<\/a><\/li>\n
  4. https:\/\/doi.org\/10.1016\/j.apradiso.2011.04.021<\/a><\/li>\n
  5. https:\/\/doi.org\/10.1007\/s00259-014-2978-1<\/a><\/li>\n
  6. https:\/\/doi.org\/10.2967%2Fjnumed.123.265763<\/a><\/li>\n
  7. https:\/\/doi.org\/10.1016\/j.semcancer.2015.07.003<\/a><\/li>\n
  8. https:\/\/doi.org\/10.1158\/1541-7786.mcr-23-0075<\/a><\/li>\n
  9. https:\/\/doi.org\/10.7150\/thno.93249<\/a><\/li>\n
  10. https:\/\/doi.org\/10.21037\/atm-23-1842<\/a><\/li>\n<\/ol>\n<\/div>\n<\/div><\/div><\/div><\/div><\/div>","protected":false},"excerpt":{"rendered":"

    Prostate-specific membrane antigen (PSMA) is a promising target to achieve a selective delivery to prostate cancer.1) Even though its significance in cancer pharmacology is scarce, radiopharmaceuticals have been taken it as the target for the therapy and diagnostic purposes. PSMA targeting is the legendary story of radiopharmaceutical discovery and development and it is of high […]<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[18],"tags":[],"class_list":["post-2390","post","type-post","status-publish","format-standard","hentry","category-blog"],"yoast_head":"\nProstate Cancer and Radiopharmaceuticals of 177Lu, 225Ac and 213Bi - PRISM BioLab<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/prismbiolab.com\/ja\/2390-2\/\" \/>\n<meta property=\"og:locale\" content=\"ja_JP\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Prostate Cancer and Radiopharmaceuticals of 177Lu, 225Ac and 213Bi - PRISM BioLab\" \/>\n<meta property=\"og:description\" content=\"Prostate-specific membrane antigen (PSMA) is a promising target to achieve a selective delivery to prostate cancer.1) Even though its significance in cancer pharmacology is scarce, radiopharmaceuticals have been taken it as the target for the therapy and diagnostic purposes. PSMA targeting is the legendary story of radiopharmaceutical discovery and development and it is of high […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/prismbiolab.com\/ja\/2390-2\/\" \/>\n<meta property=\"og:site_name\" content=\"PRISM BioLab\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-27T15:05:56+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-05-27T15:06:46+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/prismbiolab.com\/wp-content\/uploads\/2024\/07\/career-collage.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1122\" \/>\n\t<meta property=\"og:image:height\" content=\"1097\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"vera\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u57f7\u7b46\u8005\" \/>\n\t<meta name=\"twitter:data1\" content=\"vera\" \/>\n\t<meta name=\"twitter:label2\" content=\"\u63a8\u5b9a\u8aad\u307f\u53d6\u308a\u6642\u9593\" \/>\n\t<meta name=\"twitter:data2\" content=\"3\u5206\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/prismbiolab.com\\\/2390-2\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/prismbiolab.com\\\/2390-2\\\/\"},\"author\":{\"name\":\"vera\",\"@id\":\"https:\\\/\\\/prismbiolab.com\\\/#\\\/schema\\\/person\\\/c39849cfa45a5eee95d62d3998e14ac9\"},\"headline\":\"Prostate Cancer and Radiopharmaceuticals of 177Lu, 225Ac and 213Bi\",\"datePublished\":\"2026-05-27T15:05:56+00:00\",\"dateModified\":\"2026-05-27T15:06:46+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/prismbiolab.com\\\/2390-2\\\/\"},\"wordCount\":608,\"publisher\":{\"@id\":\"https:\\\/\\\/prismbiolab.com\\\/#organization\"},\"articleSection\":[\"Blog\"],\"inLanguage\":\"ja\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/prismbiolab.com\\\/2390-2\\\/\",\"url\":\"https:\\\/\\\/prismbiolab.com\\\/2390-2\\\/\",\"name\":\"Prostate Cancer and Radiopharmaceuticals of 177Lu, 225Ac and 213Bi - PRISM BioLab\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/prismbiolab.com\\\/#website\"},\"datePublished\":\"2026-05-27T15:05:56+00:00\",\"dateModified\":\"2026-05-27T15:06:46+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/prismbiolab.com\\\/2390-2\\\/#breadcrumb\"},\"inLanguage\":\"ja\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/prismbiolab.com\\\/2390-2\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/prismbiolab.com\\\/2390-2\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/prismbiolab.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Prostate Cancer and Radiopharmaceuticals of 177Lu, 225Ac and 213Bi\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/prismbiolab.com\\\/#website\",\"url\":\"https:\\\/\\\/prismbiolab.com\\\/\",\"name\":\"PRISM BioLab\",\"description\":\"PRISM BioLab MIMICS natural peptides leading to cures of the greatest health challenges\",\"publisher\":{\"@id\":\"https:\\\/\\\/prismbiolab.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/prismbiolab.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"ja\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/prismbiolab.com\\\/#organization\",\"name\":\"PRISM BioLab\",\"url\":\"https:\\\/\\\/prismbiolab.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"ja\",\"@id\":\"https:\\\/\\\/prismbiolab.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/prismbiolab.com\\\/wp-content\\\/uploads\\\/2021\\\/09\\\/prism_logo_b.jpg\",\"contentUrl\":\"https:\\\/\\\/prismbiolab.com\\\/wp-content\\\/uploads\\\/2021\\\/09\\\/prism_logo_b.jpg\",\"width\":300,\"height\":367,\"caption\":\"PRISM BioLab\"},\"image\":{\"@id\":\"https:\\\/\\\/prismbiolab.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/prismbiolab.com\\\/#\\\/schema\\\/person\\\/c39849cfa45a5eee95d62d3998e14ac9\",\"name\":\"vera\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"ja\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/e9f830f27345ae572541f7e2ee9538c9139cea2ecec346fce05674c00451c0c9?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/e9f830f27345ae572541f7e2ee9538c9139cea2ecec346fce05674c00451c0c9?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/e9f830f27345ae572541f7e2ee9538c9139cea2ecec346fce05674c00451c0c9?s=96&d=mm&r=g\",\"caption\":\"vera\"},\"url\":\"https:\\\/\\\/prismbiolab.com\\\/ja\\\/author\\\/labprzm_\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Prostate Cancer and Radiopharmaceuticals of 177Lu, 225Ac and 213Bi - PRISM BioLab","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/prismbiolab.com\/ja\/2390-2\/","og_locale":"ja_JP","og_type":"article","og_title":"Prostate Cancer and Radiopharmaceuticals of 177Lu, 225Ac and 213Bi - PRISM BioLab","og_description":"Prostate-specific membrane antigen (PSMA) is a promising target to achieve a selective delivery to prostate cancer.1) Even though its significance in cancer pharmacology is scarce, radiopharmaceuticals have been taken it as the target for the therapy and diagnostic purposes. PSMA targeting is the legendary story of radiopharmaceutical discovery and development and it is of high […]","og_url":"https:\/\/prismbiolab.com\/ja\/2390-2\/","og_site_name":"PRISM BioLab","article_published_time":"2026-05-27T15:05:56+00:00","article_modified_time":"2026-05-27T15:06:46+00:00","og_image":[{"width":1122,"height":1097,"url":"https:\/\/prismbiolab.com\/wp-content\/uploads\/2024\/07\/career-collage.jpg","type":"image\/jpeg"}],"author":"vera","twitter_card":"summary_large_image","twitter_misc":{"\u57f7\u7b46\u8005":"vera","\u63a8\u5b9a\u8aad\u307f\u53d6\u308a\u6642\u9593":"3\u5206"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/prismbiolab.com\/2390-2\/#article","isPartOf":{"@id":"https:\/\/prismbiolab.com\/2390-2\/"},"author":{"name":"vera","@id":"https:\/\/prismbiolab.com\/#\/schema\/person\/c39849cfa45a5eee95d62d3998e14ac9"},"headline":"Prostate Cancer and Radiopharmaceuticals of 177Lu, 225Ac and 213Bi","datePublished":"2026-05-27T15:05:56+00:00","dateModified":"2026-05-27T15:06:46+00:00","mainEntityOfPage":{"@id":"https:\/\/prismbiolab.com\/2390-2\/"},"wordCount":608,"publisher":{"@id":"https:\/\/prismbiolab.com\/#organization"},"articleSection":["Blog"],"inLanguage":"ja"},{"@type":"WebPage","@id":"https:\/\/prismbiolab.com\/2390-2\/","url":"https:\/\/prismbiolab.com\/2390-2\/","name":"Prostate Cancer and Radiopharmaceuticals of 177Lu, 225Ac and 213Bi - PRISM BioLab","isPartOf":{"@id":"https:\/\/prismbiolab.com\/#website"},"datePublished":"2026-05-27T15:05:56+00:00","dateModified":"2026-05-27T15:06:46+00:00","breadcrumb":{"@id":"https:\/\/prismbiolab.com\/2390-2\/#breadcrumb"},"inLanguage":"ja","potentialAction":[{"@type":"ReadAction","target":["https:\/\/prismbiolab.com\/2390-2\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/prismbiolab.com\/2390-2\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/prismbiolab.com\/"},{"@type":"ListItem","position":2,"name":"Prostate Cancer and Radiopharmaceuticals of 177Lu, 225Ac and 213Bi"}]},{"@type":"WebSite","@id":"https:\/\/prismbiolab.com\/#website","url":"https:\/\/prismbiolab.com\/","name":"PRISM BioLab","description":"PRISM BioLab MIMICS natural peptides leading to cures of the greatest health challenges","publisher":{"@id":"https:\/\/prismbiolab.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/prismbiolab.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"ja"},{"@type":"Organization","@id":"https:\/\/prismbiolab.com\/#organization","name":"PRISM BioLab","url":"https:\/\/prismbiolab.com\/","logo":{"@type":"ImageObject","inLanguage":"ja","@id":"https:\/\/prismbiolab.com\/#\/schema\/logo\/image\/","url":"https:\/\/prismbiolab.com\/wp-content\/uploads\/2021\/09\/prism_logo_b.jpg","contentUrl":"https:\/\/prismbiolab.com\/wp-content\/uploads\/2021\/09\/prism_logo_b.jpg","width":300,"height":367,"caption":"PRISM BioLab"},"image":{"@id":"https:\/\/prismbiolab.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/prismbiolab.com\/#\/schema\/person\/c39849cfa45a5eee95d62d3998e14ac9","name":"vera","image":{"@type":"ImageObject","inLanguage":"ja","@id":"https:\/\/secure.gravatar.com\/avatar\/e9f830f27345ae572541f7e2ee9538c9139cea2ecec346fce05674c00451c0c9?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/e9f830f27345ae572541f7e2ee9538c9139cea2ecec346fce05674c00451c0c9?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/e9f830f27345ae572541f7e2ee9538c9139cea2ecec346fce05674c00451c0c9?s=96&d=mm&r=g","caption":"vera"},"url":"https:\/\/prismbiolab.com\/ja\/author\/labprzm_\/"}]}},"_links":{"self":[{"href":"https:\/\/prismbiolab.com\/ja\/wp-json\/wp\/v2\/posts\/2390","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/prismbiolab.com\/ja\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/prismbiolab.com\/ja\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/prismbiolab.com\/ja\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/prismbiolab.com\/ja\/wp-json\/wp\/v2\/comments?post=2390"}],"version-history":[{"count":2,"href":"https:\/\/prismbiolab.com\/ja\/wp-json\/wp\/v2\/posts\/2390\/revisions"}],"predecessor-version":[{"id":2392,"href":"https:\/\/prismbiolab.com\/ja\/wp-json\/wp\/v2\/posts\/2390\/revisions\/2392"}],"wp:attachment":[{"href":"https:\/\/prismbiolab.com\/ja\/wp-json\/wp\/v2\/media?parent=2390"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/prismbiolab.com\/ja\/wp-json\/wp\/v2\/categories?post=2390"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/prismbiolab.com\/ja\/wp-json\/wp\/v2\/tags?post=2390"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}